Phase i study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

British Journal of Cancer

Volumn 110, Issue 5, 2014, Pages 1155-1162

  Bauer, S ^a   Hilger, R A ^a   Muhlenberg T ^a   Grabellus, F ^a   Nagarajah, J ^a   Hoiczyk, M ^a   Reichardt, A ^b   Ahrens, M ^a   Reichardt, P ^b   Grunewald, S ^a   Scheulen, M E ^a   Pustowka, A ^c   Bock, E ^d   Schuler, M ^a   Pink, D ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

GIST; Histonedeacetylase inhibitors; Imatinib resistance; KIT; LBH589; Panobinostat; Targeted therapy

Indexed keywords

CREATININE; FLUORODEOXYGLUCOSE; HISTONE H3; IMATINIB; PANOBINOSTAT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANEMIA; ARTICLE; CHILL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE LIMITING TOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRY SKIN; DYSGEUSIA; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HISTONE ACETYLATION; HUMAN; HYPOTHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MONONUCLEAR CELL; MUSCLE SPASM; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN CELL; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 84895813472     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.826     Document Type: Article

References (32)

1. Bauer S, Yu LK, Demetri GD, Fletcher JA (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66(18): 9153-9161. (Pubitemid 44521135)
2. Blanke CD, Demetri GD, Von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (2008a) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4): 620-625. (Pubitemid 351264357)
3. Blanke CD, Rankin C, Demetri GD, Ryan CW, Von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC (2008b) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4): 626-632. (Pubitemid 351264358)
4. Chin R, Lee BY (2008) Principles and Practice of Clinical Trial Medicine. Academic Press: London, UK.
5. Demetri GD, Le Cesne A, Von Mehren M, Chmielowski B, Bauer S, Chow WA, Rodenas E, McKee K, Grayzel DS, Kang Y (2010) Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. In: ASCO Gastrointestinal Cancers Symposium, Vol. 9; Orlando, FL; 22-24 January 2010 (abstract 64).
6. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von MM, Joensuu H, Badalamenti G, Blackstein M, Le CA, Schoffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG (2012) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863): 295-302.
7. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544): 1329-1338. (Pubitemid 44528723)
8. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY (2012) Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 107(1): 133-138.
9. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD, Fletcher JA (2004) Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23(22): 3999-4006. (Pubitemid 38747928)
10. Filppula AM, Laitila J, Neuvonen PJ, Backman JT (2012) Potent mechanismbased inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165(8): 2787-2798.
11. Floris G, Debiec-Rychter M, Sciot R, Stefan C, Fieuws S, Machiels K, Atadja P, Wozniak A, Faa G, Schoffski P (2009a) High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 15(12): 4066-4076.
12. Floris G, Debiec-Rychter M, Sciot R, Stefan C, Fieuws S, Machiels K, Atadja P, Wozniak A, Faa G, Schoffski P (2009b) High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 15(12): 4066-4076.
13. Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H, Kobayashi K, Yamamoto N (2012) A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 30(3): 1096-1106.
14. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE (2006) Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma- H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 66(23): 11298-11304. (Pubitemid 46009960)
15. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12(15): 4628-4635. (Pubitemid 44297814)
16. Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, Sharma S, Hengelage T, de JM (2011) Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 68(3): 805-813.
17. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, Von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29): 4764-4774. (Pubitemid 46630941)
18. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607): 708-710. (Pubitemid 36159485)
19. Heinrich MC, Marino-Enriquez A, Presnell A, Donsky RS, Griffith DJ, McKinley A, Patterson J, Taguchi T, Liang CW, Fletcher JA (2012) Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther 11(8): 1770-1780.
20. Heinrich MC, Wise S, Hood M, Smith B, Kaufman M, Lu W, Wang Y, Griffith D, Flynn D, Fletcher JA (2010) in vitro activity of novel KIT/PDGFRA switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors. Proc Am Soc Clin Oncol 28: a10007.
21. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad TG, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350): 577-580. (Pubitemid 28067289)
22. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10): 1247-1252. (Pubitemid 350106355)
23. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M, Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J, Ando Y (2012) Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs 30(5): 1950-1957.
24. Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA, Bauer S (2009) Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 69(17): 6941-6950.
25. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9): 879-894. (Pubitemid 41252840)
26. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61(22): 8118-8121. (Pubitemid 33091601)
27. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440): 1127-1134. (Pubitemid 39296599)
28. Wagner A, Morgan JA, Rosen LS, George S, Gordeon MS, Devine CM, Van den Abbeele A, Grayzel D, Demetri GD (2008) Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol 26(6): a10503.
29. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R, Bihl H, Leutner CC, Heinicke T, Hohenberger P (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6(4): 249-251. (Pubitemid 40450717)
30. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28(29): 4485-4491.
31. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37): 5541-5552. (Pubitemid 47255934)
32. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13): 1773-1782. (Pubitemid 29512308)